Tango Therapeutics (TNGX) AI Stock Analysis

• Market Cap: $519.21M
• Dividend Yield: N/A
• Average Volume (3M): 3.92M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.88
• Revenue Growth: 10.10%
• EPS Growth: -7.25%
• Country: US
• Employees: 155
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -0.36
• Shares Outstanding: 108,394,190
• 10 Day Avg. Volume: 4,399,952
• 30 Day Avg. Volume: 3,916,200
• PEG Ratio: -0.19
• Price to Book (P/B): 2.55
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.45
• Enterprise Value/Market Cap: 1.19
• Enterprise Value/Revenue: 3.66
• Enterprise Value/Gross Profit: 15.31
• Enterprise Value/Ebitda: -1.12
• 1Y Price Target: $12.00
• Price Target Upside: 150.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 46 Neutral
• Price Target: $4.50 ▼(-6.25%Downside)

Tango Therapeutics' overall stock score is primarily influenced by its financial performance, marked by persistent operational challenges and negative cash flow. Despite strong technical indicators suggesting bullish momentum, the company's poor valuation due to unprofitability tempers the outlook.

Positive Factors

Clinical Trials

Initiation of combination trials for TNG462 with Revolution Medicines' RAS(ON) inhibitors and Merck's Keytruda in 1H25.

Efficacy Update

The company provided an initial efficacy update for TNG462 with a confirmed ORR of 43% in cholangiocarcinoma.

Financial Stability

Tango ended 2024 with $257.9M in cash, which should provide an operational runway into 3Q26.

Negative Factors

Clinical Risks

Risks include negative clinical results with the lead asset, TNG462, and delays in advancing pipeline candidates.

Investor Sentiment

Investors were disappointed this update contained no numerical TNG462 efficacy data for the remaining evaluable patients, particularly pancreatic and lung which represent larger commercial opportunities.

Tango Therapeutics Business Overview & Revenue Model

Company Description

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

How the Company Makes Money

Tango Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical companies. These partnerships often involve licensing agreements, where Tango provides access to its proprietary technology or drug candidates in exchange for upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future product sales. Additionally, Tango may receive funding from research grants and government contracts to support its R&D activities, contributing to its revenue streams.

Tango Therapeutics Financial Statement Overview

Summary

Tango Therapeutics faces significant financial challenges with persistent losses, negative cash flows, and poor return on equity. Despite a strong gross profit margin and cautious leverage, the company's financial health is undermined by operational inefficiencies.

Income Statement

Tango Therapeutics shows declining revenue with a recent drop from $42.1M to $40.99M (TTM). The company has consistently operated at a loss, with negative EBIT and net profit margins. The gross profit margin is strong at 98.46%, but the net profit margin is deeply negative at -322.71%, indicating significant operational challenges.

Balance Sheet

The company maintains a moderate debt-to-equity ratio of 0.22, reflecting cautious leverage. Return on Equity is poor at -79.32%, showing inefficiencies in generating returns from equity. The equity ratio of 60.79% indicates a strong reliance on equity financing.

Cash Flow

Tango Therapeutics struggles with cash flows, as highlighted by the negative free cash flow growth rate. The operating cash flow to net income ratio is slightly negative, indicating cash outflows exceed net income. The company needs to improve its operational cash generation.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
40.99M	42.07M	36.53M	24.86M	37.04M	7.66M
	Gross Profit
40.36M	42.07M	-78.67M	20.83M	35.08M	6.03M
	EBIT
-145.87M	-145.59M	-114.17M	-111.07M	-58.19M	-52.20M
	EBITDA
-143.37M	-143.10M	-111.76M	-109.46M	-57.29M	-51.48M
	Net Income Common Stockholders
-132.26M	-130.30M	-101.74M	-108.18M	-58.23M	-51.86M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
216.72M	257.92M	336.88M	366.13M	485.25M	190.32M
	Total Assets
274.31M	316.49M	402.57M	436.47M	500.15M	207.25M
	Total Debt
36.95M	36.49M	38.92M	41.13M	1.50M	7.88M
	Net Debt
-21.49M	-33.04M	-27.46M	-18.84M	-141.24M	-20.50M
	Total Liabilities
107.55M	116.97M	149.46M	186.99M	155.41M	168.65M
	Stockholders Equity
166.76M	199.52M	253.11M	249.48M	344.75M	38.60M
Cash Flow		Free Cash Flow
-135.95M	-132.25M	-119.51M	-116.77M	-61.36M	68.97M
	Operating Cash Flow
-135.34M	-131.50M	-117.98M	-109.08M	-59.53M	70.07M
	Investing Cash Flow
127.93M	86.13M	41.43M	26.40M	-183.43M	-145.47M
	Financing Cash Flow
4.68M	47.66M	82.41M	1.61M	357.32M	80.88M

Tango Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNGX, the sentiment is Positive. The current price of 4.8 is above the 20-day moving average (MA) of 3.29, above the 50-day MA of 2.15, and above the 200-day MA of 3.81, indicating a bullish trend. The MACD of 0.85 indicates Negative momentum. The RSI at 77.36 is Negative, neither overbought nor oversold. The STOCH value of 85.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TNGX.

Tango Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FULC	66 Neutral	$367.06M	―	-0.23%	―	3087.25%	97.11%
ACIU	54 Neutral	$191.95M	―	-43.31%	―	95.23%	15.55%
Sector *	54 Neutral	$5.34B	3.36	-45.10%	3.39%	16.81%	-0.03%
RZLT	53 Neutral	$372.01M	―	-95.15%	―	―	-10.43%
TNGX	46 Neutral	$519.21M	―	-61.35%	―	10.10%	-7.25%
IKT	46 Neutral	$144.22M	―	-79.02%	―	-100.00%	38.72%
DMAC	42 Neutral	$150.52M	―	-67.25%	―	―	2.53%

Tango Therapeutics Corporate Events

Tango Therapeutics Approves Key Proposals at Annual Meeting

On June 5, 2025, Tango Therapeutics held its annual stockholders meeting where several key proposals were approved. Notably, the amendment to increase authorized common stock shares from 200 million to 400 million was passed, potentially enhancing the company’s capital structure and flexibility. Additionally, Lesley Ann Calhoun was elected as a Class I director, and PricewaterhouseCoopers, LLP was ratified as the independent accounting firm for the fiscal year ending December 31, 2025. The stockholders also approved executive compensation policies and decided on an annual frequency for future advisory votes on executive compensation.

The most recent analyst rating on (TNGX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.